Su, J., Reynier, J.-B., Fu, X., Zhong, G., Jiang, J., Escalante, R. S., Wang, Y., Aparicio, L., Izar, B., Knowles, D. A., & Rabadan, R. (2023). Smoother: a unified and modular framework for incorporating structural dependency in spatial omics data. Genome Biology, 24(1). https://doi.org/10.1186/s13059-023-03138-x

McCarthy, P. L., Attwood, K. M., Liu, X., Chen, G. L., Minderman, H., Alousi, A., Bashey, A., Lowsky, R., Miklos, D. B., Hansen, J., Westervelt, P., Yanik, G., Waller, E. K., Howard, A., Blazar, B. R., Wallace, P. K., Reshef, R., Horowitz, M. M., Maziarz, R. T., … Mohammadpour, H. (2023). Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplantation, 59(3), 334–343. https://doi.org/10.1038/s41409-023-02168-0

Xiao, M., Kondo, S., Nomura, M., Kato, S., Nishimura, K., Zang, W., Zhang, Y., Akashi, T., Viny, A., Shigehiro, T., Ikawa, T., Yamazaki, H., Fukumoto, M., Tanaka, A., Hayashi, Y., Koike, Y., Aoyama, Y., Ito, H., Nishikawa, H., … Inoue, D. (2023). BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44081-6

Fu, J., Wang, Z., Martinez, M., Obradovic, A., Jiao, W., Frangaj, K., Jones, R., Guo, X. V., Zhang, Y., Kuo, W.-I., Ko, H. M., Iuga, A., Bay Muntnich, C., Prada Rey, A., Rogers, K., Zuber, J., Ma, W., Miron, M., Farber, D. L., … Sykes, M. (2023). Plasticity of intragraft alloreactive T cell clones in human gut correlates with transplant outcomes. Journal of Experimental Medicine, 221(1). https://doi.org/10.1084/jem.20230930

A Brief Screening Tool for Assessment of Financial Toxicity. (2024). Oncology Nursing Forum. https://doi.org/10.1188/24.onf.17-23

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncology, 20(12), 717–726. https://doi.org/10.2217/fon-2023-0849

Banerjee, D., Boboila, S., Okochi, S., Angelastro, J. M., Kadenhe-Chiweshe, A. V., Lopez, G., Califano, A., Connolly, E. P., Greene, L. A., & Yamashiro, D. J. (2023). Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. Cancer Research Communications, 3(12), 2518–2530. https://doi.org/10.1158/2767-9764.crc-23-0154

Xu, X., Chen, L., Nunez-Smith, M., Clark, M., Ferris, J. S., Hershman, D. L., & Wright, J. D. (2024). Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology, 180, 118–125. https://doi.org/10.1016/j.ygyno.2023.11.029

Melms, J. C., Ho, P., Rogava, M., & Izar, B. (2023). From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6. Genes & Immunity, 25(1), 82–84. https://doi.org/10.1038/s41435-023-00224-9

Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Thompson, A. M., Rea, D. W., Stos, P. M., Shepherd, L. E., Stambolic, V., & Parulekar, W. R. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology, 41(35), 5356–5362. https://doi.org/10.1200/jco.23.00296

Hong, J. S., Shamim, A., Atta, H., Nonnecke, E. B., Merl, S., Patwardhan, S., Manell, E., Gunes, E., Jordache, P., Chen, B., Lu, W., Shen, B., Dionigi, B., Kiran, R. P., Sykes, M., Zorn, E., Bevins, C. L., & Weiner, J. (2024). Application of enzyme-linked immunosorbent assay to detect antimicrobial peptides in human intestinal lumen. Journal of Immunological Methods, 525, 113599. https://doi.org/10.1016/j.jim.2023.113599

Accordino, M. K., Lee, S., Leu, C. S., Levin, B., Trivedi, M. S., Crew, K. D., Kalinsky, K., Raghunathan, R., Faheem, K., Harden, E., Taboada, A., de Oliveira, B. D., Larson, E., Franks, L., Honan, E., Law, C., & Hershman, D. L. (2023). Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. Breast Cancer Research and Treatment, 204(1), 49–59. https://doi.org/10.1007/s10549-023-07172-y

Freedberg, D. E., Segall, L., Liu, B., Jacobson, J. S., Mohan, S., George, V., Kumar, R., Neugut, A. I., & Radhakrishnan, J. (2023). International Variability in the Epidemiology, Management, and Outcomes of CKD and ESKD: A Systematic Review. Kidney360, 5(1), 22–32. https://doi.org/10.34067/kid.0000000000000335

Stokes, M. E., Vasciaveo, A., Small, J. C., Zask, A., Reznik, E., Smith, N., Wang, Q., Daniels, J., Forouhar, F., Rajbhandari, P., Califano, A., & Stockwell, B. R. (2024). Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers. Cell Chemical Biology, 31(4), 805-819.e9. https://doi.org/10.1016/j.chembiol.2023.11.007

O’Neil, D. S., Martei, Y. M., Crew, K. D., Castillo, B. S., Costa, P., Lim, T., Michel, A., Rubin, E., Goel, N., Hurley, J., Lopes, G., & Antoni, M. H. (2023). Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open, 6(12), e2346223. https://doi.org/10.1001/jamanetworkopen.2023.46223

Abusamak, A.-A., Abusamak, M., Al-Abbadi, M., Rayyan, A., Oran, O., Mohyuddin, G. R., Kelkar, A. H., Goodman, A. M., Chakraborty, R., Cliff, E. R. S., & Al Hadidi, S. (2024). Use of subjective minimizing language at hematology and oncology conferences: A systematic review. Journal of Cancer Policy, 39, 100461. https://doi.org/10.1016/j.jcpo.2023.100461

Smith, N., Reznik, E., Bisikirska, B., Polychronidou, V., Wang, Q., Zask, A., Forouhar, F., Califano, A., & Stockwell, B. R. (2023). Kinases Controlling Stability of the Oncogenic MYCN Protein. ACS Medicinal Chemistry Letters, 14(12), 1664–1672. https://doi.org/10.1021/acsmedchemlett.3c00274

Ford, M., Orlando, E., & Amengual, J. E. (2023). EBV Reactivation and Lymphomagenesis: More Questions than Answers. Current Hematologic Malignancy Reports, 18(6), 226–233. https://doi.org/10.1007/s11899-023-00708-5

Sanft, T., Harrigan, M., McGowan, C., Cartmel, B., Zupa, M., Li, F.-Y., Ferrucci, L. M., Puklin, L., Cao, A., Nguyen, T. H., Neuhouser, M. L., Hershman, D. L., Basen-Engquist, K., Jones, B. A., Knobf, T., Chagpar, A. B., Silber, A., Tanasijevic, A., Ligibel, J. A., & Irwin, M. L. (2023). Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal of Clinical Oncology, 41(34), 5285–5295. https://doi.org/10.1200/jco.23.00871

Lawal, K. O., Nilan, L., Amenta, J., McGuinness, J. E., Kukafka, R., & Crew, K. D. (2023). Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions. Cancer Prevention Research, 16(12), 661–667. https://doi.org/10.1158/1940-6207.capr-23-0181

Dix‑Peek, T., Dickens, C., Augustine, T., Phakathi, B., Van Den Berg, E., Joffe, M., Ayeni, O., Cubasch, H., Nietz, S., Mathew, C., Hayat, M., Neugut, A., Jacobson, J., Ruff, P., & Duarte, R. (2023). FGFR2 genetic variants in women with breast cancer. Molecular Medicine Reports, 28(6). https://doi.org/10.3892/mmr.2023.13113

Dercle, L., Yang, M., Gönen, M., Flynn, J., Moskowitz, C. S., Connors, D. E., Yang, H., Lu, L., Reidy-Lagunes, D., Fojo, T., Karovic, S., Zhao, B., Schwartz, L. H., & Henick, B. S. (2023). Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials. European Radiology, 33(12), 9254–9261. https://doi.org/10.1007/s00330-023-09862-z

Kostyrko, K., Román, M., Lee, A. G., Simpson, D. R., Dinh, P. T., Leung, S. G., Marini, K. D., Kelly, M. R., Broyde, J., Califano, A., Jackson, P. K., & Sweet-Cordero, E. A. (2023). UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39591-2

Chatila, W. K., Walch, H., Hechtman, J. F., Moyer, S. M., Sgambati, V., Faleck, D. M., Srivastava, A., Tang, L., Benhamida, J., Ismailgeci, D., Campos, C., Wu, F., Chang, Q., Vakiani, E., de Stanchina, E., Weiser, M. R., Widmar, M., Yantiss, R. K., Shah, M. A., … Yaeger, R. (2023). Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nature Communications, 14(1). https://doi.org/10.1038/s41467-022-35592-9

Falchook, G., Rasco, D., Papadopoulos, K., Parikh, A., Mahipal, A., Messersmith, W., Manji, G., Fu, S., Sherman, E., Fein, D., Krop, J., Korth, C., Wang, J., Sharma, M., Spigel, D., Filipovic, A., & Wainberg, Z. (2023). 128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab. Immuno-Oncology and Technology, 20, 100600. https://doi.org/10.1016/j.iotech.2023.100600

Hughes, M., & Lentzsch, S. (2023). Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis. Therapeutics and Clinical Risk Management, Volume 19, 1063–1074. https://doi.org/10.2147/tcrm.s325859

Neugut, A. I., & Lebwohl, B. (2023). Early Onset Colorectal Cancer: A Hypothesis. The Oncologist, 28(12), 1015–1016. https://doi.org/10.1093/oncolo/oyad274

Ng, J. Q., Jafarov, T. H., Little, C. B., Wang, T., Ali, A. M., Ma, Y., Radford, G. A., Vrbanac, L., Ichinose, M., Whittle, S., Hunter, D. J., Lannagan, T. R. M., Suzuki, N., Goyne, J. M., Kobayashi, H., Wang, T. C., Haynes, D. R., Menicanin, D., Gronthos, S., … Mukherjee, S. (2023). Loss of Grem1-lineage chondrogenic progenitor cells causes osteoarthritis. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42199-1

Mishkin, A. D., Prince, E. J., Leimbach, E. J., Mapara, M. Y., & Carroll, C. P. (2023). Psychiatric comorbidities in adults with sickle cell disease: A narrative review. British Journal of Haematology, 203(5), 747–759. Portico. https://doi.org/10.1111/bjh.18981

Kukafka, R., Millery, M., Pan, S., Silverman, T. B., Zhang, T., McGuinness, J. E., Crew, K. D., & Aguirre, A. N. (2023). Cognitive and emotional factors related to COVID-19 among high-risk ethnically diverse adults at the onset of the New York City outbreak: A cross-sectional survey. Humanities and Social Sciences Communications, 10(1). https://doi.org/10.1057/s41599-023-01679-x

Mellgard, G., Stoffel, E., Michel, A., Iqbal, F., Provenzano, A., Akpan, I. J., Amengual, J., & Pro, B. (2023). Hypereosinophilic syndrome with leptomeningeal involvement: a not-so-classical case report of classical Hodgkin Lymphoma. Leukemia & Lymphoma, 64(13), 2208–2213. https://doi.org/10.1080/10428194.2023.2252124

Gerall, C. D., Obradovic, A. Z., Betcher, M. C., Debelenko, L., Lee, A., Dallos, M. C., & Fallon, E. M. (2023). Characterization of gene expression and biological pathways in Wilms tumor. Journal of Pediatric Surgery Open, 4, 100095. https://doi.org/10.1016/j.yjpso.2023.100095

Manji, G. A., Lee, S., Del Portillo, A., May, M., Ana, S. S., Alouani, E., Sender, N., Negri, T., Gautier, K., Ge, L., Fan, W., Xie, M., Sethi, A., Schrope, B., Tan, A. C., Park, H., Oberstein, P. E., Shah, M. A., & Raufi, A. G. (2023). Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. JAMA Oncology, 9(12), 1702. https://doi.org/10.1001/jamaoncol.2023.4423

Raghavan, R., Coppola, U., Wu, Y., Ihewulezi, C., Negrón-Piñeiro, L. J., Maguire, J. E., Hong, J., Cunningham, M., Kim, H. J., Albert, T. J., Ali, A. M., Saint-Jeannet, J.-P., Ristoratore, F., Dahia, C. L., & Di Gregorio, A. (2023). Gene expression in notochord and nuclei pulposi: a study of gene families across the chordate phylum. BMC Ecology and Evolution, 23(1). https://doi.org/10.1186/s12862-023-02167-1

Fu, J., Li, S., Ma, H., Yang, J., Pagnotti, G. M., Brown, L. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2023). The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39769-8

Chen, X., Li, Y., Zhu, F., Xu, X., Estrella, B., Pazos, M. A., McGuire, J. T., Karagiannis, D., Sahu, V., Mustafokulov, M., Scuoppo, C., Sánchez-Rivera, F. J., Soto-Feliciano, Y. M., Pasqualucci, L., Ciccia, A., Amengual, J. E., & Lu, C. (2023). Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39990-5

Suzuki, Y., Chen, L., Ferris, J. S., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., de Meritens, A. B., Accordino, M., Hershman, D. L., & Wright, J. D. (2024). Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer. Gynecologic Oncology, 180, 14–23. https://doi.org/10.1016/j.ygyno.2023.11.010

Ayeni, O. A., Joffe, M., Mapanga, W., Chen, W. C., O’Neil, D. S., Phakathi, B., Nietz, S., Buccimazza, I., Čačala, S., Stopforth, L. W., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ramiah, D., Ruff, P., Cubasch, H., Chirwa, T., McCormack, V., Micklesfield, L. K., & Norris, S. A. (2023). Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study. Breast Cancer Research, 25(1). https://doi.org/10.1186/s13058-023-01603-w

Lichtenstein, M. R. L., Beauchemin, M. P., Raghunathan, R., Lee, S., Doshi, S. D., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2024). Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs. JCO Oncology Practice, 20(1), 85–92. https://doi.org/10.1200/op.23.00205

Kinslow, C. J., Kumar, P., Olfson, M., Wall, M. M., Petridis, P. D., Horowitz, D. P., Wang, T. J. C., Kachnic, L. A., Cheng, S. K., Prigerson, H. G., Yu, J. B., & Neugut, A. I. (2023). Prognosis and risk of suicide after cancer diagnosis. Cancer, 130(4), 588–596. Portico. https://doi.org/10.1002/cncr.35118

Kanter, J., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Gupta, A. O., Zhang, L., Sheldon-Waniga, E., Gallagher, M., Gruppioni, K., Chawla, A., Elliot, H., Pierciey, F. J., Walters, M. C., & Tisdale, J. F. (2023). Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up. Blood, 142(Supplement 1), 1051–1051. https://doi.org/10.1182/blood-2023-174229

Shadman, M., Tedeschi, A., Mohseninejad, L., Yang, K., Lamanna, N., Xu, S., Cohen, A. C., Challagulla, S., Xue, M., Williams, R., O’Brien, S. M., Brown, J. R., & Tam, C. S. (2023). Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison. Blood, 142(Supplement 1), 4655–4655. https://doi.org/10.1182/blood-2023-179222

Wang, E. S., Jonas, B. A., Watts, J. M., Jurcic, J., Ferrell, P. B., Dinner, S. N., Yang, J., Seiter, K., Mims, A., Donnellan, W. B., Blum, W., & Cortes, J. (2023). Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 142(Supplement 1), 6047–6047. https://doi.org/10.1182/blood-2023-187584

Diefenbach, C. S., Jegede, O., Ansell, S. M., Steidl, C., Natkunam, Y., Scott, D. W., Mehta-Shah, N., Amengual, J. E., Forlenza, C. J., Cole, P. D., Bartlett, N. L., David, K. A., Advani, R. H., Ambinder, R. F., Thomas, S., Ibrahimi, S., & Kahl, B. S. (2023). Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412). Blood, 142(Supplement 1), 607–607. https://doi.org/10.1182/blood-2023-184531

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 424–424. https://doi.org/10.1182/blood-2023-186822

Chakraborty, R., Bhutani, D., Mapara, M., Reshef, R., Maurer, M. S., Radhakrishnan, J., & Lentzsch, S. (2023). Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program. Blood, 142(Supplement 1), 4780–4780. https://doi.org/10.1182/blood-2023-187214

Mohan, M., Shah, N., Luan, D., Monge, J., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., Zangari, M., Al Hadidi, S., Cooper, D. L., Lentzsch, S., van Rhee, F., D’Souza, A., Szabo, A., … Chakraborty, R. (2023). Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood, 142(Supplement 1), 545–545. https://doi.org/10.1182/blood-2023-174875

Brown, J. R., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., … Shadman, M. (2023). Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). Blood, 142(Supplement 1), 202–202. https://doi.org/10.1182/blood-2023-174289

Cortes, J., Jurcic, J., Baer, M. R., Blum, W., Ferrell, P. B., Jonas, B. A., Lee, S., Mims, A., Patel, S. A., Schiller, G. J., Yang, J., & Watts, J. M. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood, 142(Supplement 1), 2888–2888. https://doi.org/10.1182/blood-2023-187861

Daver, N., Zeidner, J. F., Yuda, J., Watts, J. M., Levis, M. J., Fukushima, K., Ikezoe, T., Ogawa, Y., Brandwein, J., Wang, E. S., Miyazaki, Y., Pardee, T., Hosono, N., Shima, T., Yokoyama, H., Asada, N., Jurcic, J., Cai, H., Watanabe, A., … Erba, H. P. (2023). Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood, 142(Supplement 1), 2911–2911. https://doi.org/10.1182/blood-2023-179252